Literature DB >> 2476484

Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120.

C Thiriart1, M Francotte, J Cohen, C Collignon, A Delers, S Kummert, C Molitor, D Gilles, P Roelants, F van Wijnendaele.   

Abstract

Mouse mAb reactive to the HIV-1 envelope glycoprotein precursor gp160 of the HTLVIII(B) isolate were characterized in radioimmunoprecipitation and immunoblot tests with the use of HTLVIII(B) isolate as Ag. The reactivities of these mAb were also measured in a capture enzyme immunoassay and in radioimmunoprecipitation assay by using gp160 and gp120 expressed as vaccinia recombinants. Striking differences in exposure of specific epitopes were noted between the gp120 component of the gp160 precursor and the fully processed gp120 in both tests. These conformational rearrangements affecting the gp120 moiety of the HIV-1 envelope glycoprotein might have important implications on its immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476484

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

2.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

3.  A human CD4+ T-cell line expresses functional CD64 (Fc gamma RI), CD32 (Fc gamma RII), and CD16 (Fc gamma RIII) receptors but these do not enhance the infectivity of HIV-1-IgG complexes.

Authors:  L McLain; N J Dimmock
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

4.  Nuclear export of the human immunodeficiency virus type 1 nucleocytoplasmic shuttle protein Rev is mediated by its activation domain and is blocked by transdominant negative mutants.

Authors:  A M Szilvay; K A Brokstad; R Kopperud; G Haukenes; K H Kalland
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

5.  Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1.

Authors:  V Robert; M Resnicoff; J C Chermann; C Devaux
Journal:  Mol Cell Biochem       Date:  1991-04-10       Impact factor: 3.396

6.  Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.

Authors:  J P Langedijk; N K Back; E Kinney-Thomas; C Bruck; M Francotte; J Goudsmit; R H Meloen
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  Carbohydrate binding properties of the envelope glycoproteins of human immunodeficiency virus type 1.

Authors:  M Haidar; N Seddiki; J C Gluckman; L Gattegno
Journal:  Glycoconj J       Date:  1992-12       Impact factor: 2.916

8.  Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1.

Authors:  J P Moore; R L Willey; G K Lewis; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.

Authors:  J McKeating; P Balfe; P Clapham; R A Weiss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

10.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.